Mather Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Mather Group’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-450	Closed	-$666	–	2097
2024 Q2	$666	Buy	+450	New	+$4.71K	﹤0.01%	2039

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mather Group's RIGL Position: Q3 2024 in Review

Mather Group sold out of Rigel Pharmaceuticals (RIGL) in Q3 2024, closing a stake of 450 shares — an estimated $666 sold.

Mather Group first reported a position in RIGL in Q2 2024 and held it in 1 quarter. The position peaked at $666 in Q2 2024. 93 funds tracked by Wall St. Rank hold RIGL as of Q3 2024.

Mather Group reported no remaining Rigel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Mather Group sold 450 Rigel Pharmaceuticals shares in Q3 2024, an estimated $666.
Mather Group first reported a position in Rigel Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Mather Group's Rigel Pharmaceuticals position peaked at $666 in Q2 2024.
93 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.